Infant acute lymphoblastic leukemia (ALL) is a rare disease that represents around 4% of all childhood ALL cases. The Interfant-21 study is testing a new treatment plan for infants with a specific type of ALL called KMT2A-rearranged ALL. This type of leukaemia is less sensitive to standard treatment and as a result this often leads to poorer outcomes for these patients. Unfortunately, there have been no significant improvements in treatment in the last few decades.
Patients enrolled on the Interfant-21 study will be given at least one course of the immunotherapy drug ‘blinatumomab’ alongside the standard chemotherapy treatment they usually receive. Recent studies show that Blinatumomab is safe for infants and can help improve patient outcomes without too many side effects.
The Interfant-21 study will test if blinatumomab is effective in treating infants who have just been diagnosed with KMT2A-rearranged ALL. It will also compare the outcomes of these patients with what was seen in the past in the Interfant-06 study.
Disease Stage – Newly Diagnosed
Patient Age Range – 0-1 years old at the time of diagnosis of ALL
- National – ANZCHOG
- International – Princess Máxima Center for Paediatric Oncology